“compound 23” is an oral, selective Factor XIa inhibitor intended as an anticoagulation agent. Since the clinical translatability of FXIa inhibition in preclinical models hasn’t been established, this program was driven by activity in in vitro human plasma coagulation assays. The team was able to turn a 0.6 uM hit originally from a complement [...]
< 1 minute read
Sep. 18, 2021
Compound 23: A Selective Oral Serine Protease FXia Inhibitor
"compound 23"
selective oral serine protease FXia inhibitor projected BID dosing in patients from 1.8k cmpd protease inh. screen + SBDD J. Med. Chem., Jun. 17, 2020 Novartis (NIBR), Basel, Switzerland
Loading...
